oxazoles has been researched along with Hyperlipemia in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (30.77) | 18.7374 |
| 1990's | 2 (15.38) | 18.2507 |
| 2000's | 6 (46.15) | 29.6817 |
| 2010's | 1 (7.69) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, CT; Cheng, JT; Cheng, KC; Lin, KC; Niu, CS; Wu, HT | 1 |
| Aragoncillo, P; Cachofeiro, V; Cediel, E; de las Heras, N; Lahera, V; Oubiña, MP; Sanz-Rosa, D | 1 |
| Bogdański, P; Bryl, W; Cymerys, M; Kujawska-Łuczak, M; Miczke, A; Pupek-Musialik, D | 1 |
| Biller, SA; Cap, M; Chandrasena, G; Chang, SY; Chen, S; Cheng, L; Cheng, PT; Devasthale, PV; Doweyko, A; Farrelly, D; Golla, R; Grover, G; Hariharan, N; Harrity, T; Humphreys, WG; Jeon, Y; Ma, Z; Moore, L; Qu, F; Ren, J; Ryono, DE; Sasseville, VG; Seethala, R; Selan, F; Shao, C; Sleph, P; Sun, W; Tieman, A; Wang, W; Wetterau, JR; Zhang, H | 1 |
| Biller, S; Cap, M; Chen, S; Cheng, PT; Chu, C; Devasthale, P; Farrelly, D; Fenderson, W; Gregg, R; Gu, L; Hariharan, N; Harrity, T; Jeon, Y; Kunselman, L; Mookhtiar, KA; Ponticiello, R; Qu, F; Ren, J; Ryono, D; Seethala, R; Shao, C; Tieman, A; Wang, W; Wetterau, J; Yang, WP; Zhang, H; Zhou, M | 1 |
| Ernsberger, P; Kossover, R; Previs, SF; Velliquette, RA | 1 |
| Kajiyama, G; Kawamoto, T; Kubota, S; Maruhashi, A; Nakao, S; Tsunoda, Y; Yamada, K | 1 |
| Abid, S; Grove, RI; Hartl, KS; Kowala, MC; Mazzucco, CE; Seiler, SM; Warr, GA | 1 |
| Beucler, I; Dairou, F; Février, B; Scemama, M | 1 |
| Reid, JL | 1 |
| Kobayakawa, T; Osuga, K; Yasuda, H | 1 |
| Blumenbach, L; Kiesselbach, NH; Lehnert, J | 1 |
| Parkinson, TM; Schultz, JR; Schurr, PE | 1 |
1 review(s) available for oxazoles and Hyperlipemia
| Article | Year |
|---|---|
Rilmenidine: a clinical overview.
Topics: Albuminuria; Animals; Antihypertensive Agents; Diabetic Angiopathies; Humans; Hyperlipidemias; Hypertension; Hypertrophy, Left Ventricular; Insulin Resistance; Oxazoles; Rilmenidine; Treatment Outcome | 2000 |
3 trial(s) available for oxazoles and Hyperlipemia
| Article | Year |
|---|---|
[The effect of analysed hypotensive drugs on certain metabolic parameters].
Topics: Adult; Antihypertensive Agents; Diabetes Mellitus, Type 2; Felodipine; Female; Humans; Hyperlipidemias; Hypertension; Hyperuricemia; Indoles; Male; Metabolic Syndrome; Middle Aged; Oxazoles; Rilmenidine | 2003 |
[Effects of rilmenidine (hyperium) on lipid balance in hyperlipidemic hypertensive patients. Randomized, controlled, double-blind 8-week study vs. captopril in parallel groups].
Topics: Antihypertensive Agents; Captopril; Double-Blind Method; Female; Humans; Hypercholesterolemia; Hyperlipidemias; Hypertension; Lipids; Male; Middle Aged; Oxazoles; Rilmenidine; Time Factors | 1996 |
[Multicentric clinical proof of a new oral antidiabetic glisoxepide (BS 4231). 3. Results of tolerance tests].
Topics: Alanine Transaminase; Aspartate Aminotransferases; Azepines; Blood Glucose; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Diabetes Mellitus; Drug Evaluation; Drug Hypersensitivity; Gastrointestinal Diseases; Humans; Hyperlipidemias; Hypoglycemic Agents; Kidney Diseases; Oxazoles; Paresthesia; Photosensitivity Disorders; Sulfonylurea Compounds; Time Factors | 1974 |
9 other study(ies) available for oxazoles and Hyperlipemia
| Article | Year |
|---|---|
A novel mechanism for decreasing plasma lipid level from imidazoline I-1 receptor activation in high fat diet-fed mice.
Topics: Animals; Dietary Fats; Feeding Behavior; Gene Expression Regulation; Hep G2 Cells; Humans; Hyperlipidemias; Imidazoline Receptors; Intracellular Signaling Peptides and Proteins; Lipids; Liver; Male; Mice; Mice, Inbred C57BL; Oxazoles; Oxidation-Reduction; Receptors, Cytoplasmic and Nuclear; Rilmenidine; Signal Transduction | 2011 |
Comparison between the effects of mixed dyslipidaemia and hypercholesterolaemia on endothelial function, atherosclerotic lesions and fibrinolysis in rabbits.
Topics: Acetylcholine; Animals; Aorta; Arteriosclerosis; Bridged Bicyclo Compounds, Heterocyclic; Diet; Endothelium, Vascular; Enzyme Inhibitors; Fibrinolysis; Hypercholesterolemia; Hyperlipidemias; Hypertriglyceridemia; In Vitro Techniques; Male; Models, Animal; NG-Nitroarginine Methyl Ester; Nitric Oxide Synthase; Oxazoles; Plasminogen Activator Inhibitor 1; Rabbits; Thromboxane A2; Tissue Plasminogen Activator; Vasoconstrictor Agents | 2003 |
Design and synthesis of N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5- methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine [Muraglitazar/BMS-298585], a novel peroxisome proliferator-activated receptor alpha/gamma dual agonist with efficacious glucose and
Topics: Adipocytes; Animals; Blood Glucose; Cell Line; Diabetes Mellitus, Type 2; Fatty Acids; Glycine; Humans; Hyperlipidemias; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Male; Mice; Mice, Obese; Oxazoles; PPAR alpha; PPAR gamma; Transcriptional Activation; Triglycerides | 2005 |
Muraglitazar, a novel dual (alpha/gamma) peroxisome proliferator-activated receptor activator, improves diabetes and other metabolic abnormalities and preserves beta-cell function in db/db mice.
Topics: Adiponectin; Animals; Blood Glucose; Corticosterone; Diabetes Mellitus, Type 2; Diet; Female; Glycine; Hyperlipidemias; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Liver; Mice; Obesity; Oxazoles; Peroxisome Proliferator-Activated Receptors; Rosiglitazone; Thiazolidinediones | 2006 |
Lipid-lowering actions of imidazoline antihypertensive agents in metabolic syndrome X.
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-2 Receptor Antagonists; Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Antihypertensive Agents; Cell Membrane; Cholesterol; Clonidine; Disease Models, Animal; Female; Guanabenz; Hyperlipidemias; Imidazoles; Imidazoline Receptors; Liver; Male; Metabolic Syndrome; Oxazoles; Rats; Rats, Inbred SHR; Receptors, Drug; Rilmenidine; Triglycerides | 2006 |
Effects of ethyl-2-(4-chlorophenyl)-5-ethoxy-4-oxazole acetate (Y-9738) on the serum lipids of patients with hyperlipidemia and/or hypo-HDL-emia.
Topics: Adult; Aged; Apolipoproteins A; Aspartate Aminotransferases; Bile; Cholesterol; Cholesterol, HDL; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids; Lipoproteins, HDL; Male; Middle Aged; Oxazoles; Phospholipids; Time Factors; Triglycerides | 1984 |
Prostacyclin agonists reduce early atherosclerosis in hyperlipidemic hamsters. Octimibate and BMY 42393 suppress monocyte chemotaxis, macrophage cholesteryl ester accumulation, scavenger receptor activity, and tumor necrosis factor production.
Topics: Animals; Aorta, Thoracic; Arteriosclerosis; Chemotaxis; Cholesterol Esters; Cricetinae; Epoprostenol; Hyperlipidemias; Imidazoles; Macrophages; Male; Membrane Proteins; Monocytes; Oxazoles; Phenoxyacetates; Receptors, Immunologic; Receptors, Lipoprotein; Receptors, Scavenger; Scavenger Receptors, Class B; Tumor Necrosis Factor-alpha | 1993 |
Experimental hyper-beta-lipoproteinemia and its amelioration by a novel hypolipidemic agent.
Topics: Animals; Cholesterol; Cholesterol, Dietary; Clofibrate; Disease Models, Animal; Dose-Response Relationship, Drug; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins, LDL; Male; Oxazoles; Propylthiouracil; Rats; Triglycerides | 1978 |
Triton-induced hyperlipidemia in rats as an animal model for screening hypolipidemic drugs.
Topics: Animals; Carboxylic Acids; Cholesterol; Clofibrate; Disease Models, Animal; Fasting; Hyperlipidemias; Hypolipidemic Agents; Injections, Intraperitoneal; Injections, Intravenous; Kinetics; Male; Naphthalenes; Nicotinic Acids; Oxazoles; Phenols; Polysaccharides; Pyrrolidines; Rats; Surface-Active Agents; Thyroxine; Triglycerides; Triparanol | 1972 |